Lilly’s Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer’s Disease

Japan is the second major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024 INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ — The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four…